Tesamorelin
2 mg
GHRH Analogue (Egrifta analogue)
Tesamorelin
Stabilised GHRH analogue for visceral adiposity and GH research.
Prices in AUD. Tax included.
Research Use Only: FOR LABORATORY RESEARCH USE ONLY. Not for human consumption, injection, or therapeutic use. All products are sold strictly as research chemicals. By purchasing, you confirm you are 18+ and agree to use products solely for legitimate research purposes.
Description
Tesamorelin is a stabilised growth hormone-releasing hormone (GHRH) analogue with a trans-3-hexenoic acid modification that enhances its stability and bioavailability. It is one of the few GHRH analogues with extensive clinical research data, particularly regarding visceral adipose tissue reduction.
Specifications
- SKU
- TESA-2MG
- Size
- 2 mg
- Form
- Lyophilised Powder
- Purity
- >99%
- Storage
- -20°C (lyophilised), 2-8°C (reconstituted)
- Shipping
- Australia Post — 3–5 business days
Research Summary
Clinical research demonstrates Tesamorelin selectively stimulates pituitary GH secretion, resulting in physiological GH pulsatility. Studies show significant reductions in visceral adipose tissue (VAT) with preserved subcutaneous fat, and improvements in lipid profiles. It maintains the hypothalamic-pituitary feedback loop unlike exogenous GH.
Testing Protocol
- HPLC Purity Analysis
- Mass Spectrometry Identity Verification
- Endotoxin Screening (LAL Test)